3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Recurrence
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Advanced Pancreatic Cancer
1
Interventions
X-Rays
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
4
Melphalan
4
fludarabine
3
Granulocyte Colony-Stimulating Factor
3
Cyclophosphamide
3
Busulfan
3
Biopsy
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
ensartinib
2
Vemurafenib
2
Trabectedin
2
Thiotepa
2
Temozolomide
2
Sirolimus
2
Mesna
2
LY3023414
2
Cytoreduction Surgical Procedures
2
Cisplatin
2
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdomyosarcoma
×
pegylated granulocyte colony-stimulating factor
×
Gastrointestinal
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled